Attached files
| file | filename |
|---|---|
| EX-99.4 - CONSENT OF THOMAS FOLINSBEE, DIRECTOR NOMINEE - XYNOMIC PHARMACEUTICALS HOLDINGS, INC. | fs12017a1ex99iv_bisoncap.htm |
| EX-99.5 - CONSENT OF NING WANG, DIRECTOR NOMINEE - XYNOMIC PHARMACEUTICALS HOLDINGS, INC. | fs12017a1ex99v_bisoncap.htm |
| EX-10.9 - FORM OF INDEMNITY AGREEMENT - XYNOMIC PHARMACEUTICALS HOLDINGS, INC. | fs12017a1ex10ix_bisoncap.htm |
| EX-8.1 - FORM OF TAX OPINION OF HUNTER TAUBMAN FISCHER & LI LLC - XYNOMIC PHARMACEUTICALS HOLDINGS, INC. | fs12017a1ex8i_bisoncap.htm |
| EX-5.2 - FORM OF OPINION OF HUNTER TAUBMAN FISCHER & LI LLC - XYNOMIC PHARMACEUTICALS HOLDINGS, INC. | fs12017a1ex5ii_bisoncap.htm |
| EX-5.1 - FORM OF OPINION OF OGIER - XYNOMIC PHARMACEUTICALS HOLDINGS, INC. | fs12017a1ex5i_bisoncap.htm |
| EX-3.2 - FORM OF AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION - XYNOMIC PHARMACEUTICALS HOLDINGS, INC. | fs12017a1ex3ii_bisoncap.htm |
| S-1/A - AMENDED REGISTRATION STATEMENT - XYNOMIC PHARMACEUTICALS HOLDINGS, INC. | fs12017a1_bisoncap.htm |
Exhibit 23.1
Independent Registered Public Accounting Firm’s Consent
We consent to the inclusion in this Registration Statement of Bison Capital Acquisition Corp. (the “Company”) on Amendment No. 1 to Form S-1, File No. 333-218404, of our report dated February 28, 2017, which includes an explanatory paragraph as to the Company’s ability to continue as a going concern, with respect to our audit of the financial statements of Bison Capital Acquisition Corp. as of December 31, 2016 and for the period from October 7, 2016 (inception) through December 31, 2016, which report appears in the Prospectus, which is part of this Registration Statement. We also consent to the reference to our Firm under the heading “Experts” in such Prospectus.
/s/ Marcum llp
Marcum llp
New York, NY
June 15, 2017